Myocardial interaction of apixaban after experimental acute volume overload

J Int Med Res. 2022 Nov;50(11):3000605221137474. doi: 10.1177/03000605221137474.

Abstract

Objective: Acute volume overload (AVO) induces early ischemia-like changes in intramyocardial arteries. We investigated whether the Factor Xa (FXa) inhibitor apixaban interacts with the myocardium early after AVO.

Methods: Fifty-five syngeneic Fisher rats underwent surgical abdominal aortocaval fistula to induce AVO. Among them, 17 rats were treated with apixaban (10 mg/kg/day). The myocardial outcome was studied using histological analysis and by measuring atrial natriuretic peptide (ANP) and matrix metalloprotease 9 (MMP9) gene expression.

Results: After 3 days, the total number of intramyocardial arteries was significantly increased in the AVO+apixaban (AVO+A) group compared with that in the AVO group (12.0 ± 1.2 and 10.2 ± 1.5, point score units, respectively). In the AVO+A group, there were significantly more edematous nuclei in myocardial arteries in the right and left ventricle compared with that in the AVO group. ANP and MMP9 expression levels continued to increase significantly in the AVO+A group compared with those in the AVO group.

Conclusion: Apixaban interacts with intramyocardial arteries in the left and right ventricles after AVO and ANP and MMP9 expression levels increased. Thus, the myocardial effect of Factor Xa inhibition needs to be monitored after AVO.

Keywords: Factor Xa inhibition; acute volume overload; apixaban; atrial natriuretic peptide; matrix metalloprotease 9; myocardial artery; rat.

MeSH terms

  • Animals
  • Atrial Natriuretic Factor
  • Factor Xa / metabolism
  • Heart Failure*
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Myocardium / metabolism
  • Rats
  • Water-Electrolyte Imbalance*

Substances

  • Atrial Natriuretic Factor
  • apixaban
  • Matrix Metalloproteinase 9
  • Factor Xa